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 Materials and Methods 
2-(((ethylthio)carbonothioyl)thio)-2-methylpropanoic acid (CTA)S1 was synthesised according to protocols 
described in the literature. 8-Hydroxypyrene-1,3,6-trisulfonic acid trisodium salt (HPTS) was purchased from 
Sigma-Aldrich® and p-xylene-bis-pyridinium bromide (DPX) was purchased from InvitrogenTM. Egg yolk L-α-
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phosphatidylcholine (EYPC) was purchased from Avanti Polar Lipids, Inc. All other chemicals were purchased 
from Sigma-Aldrich®, Scharlau, Panreac Química SLU, Fisher Scientific® or Acros® and used without further 
purification. All solvents were HPLC grade, purchased from Sigma-Aldrich® or Fisher Scientific®, and used 
without further purification. 
Nuclear Magnetic Resonance (NMR) spectra were recorded on either a Bruker Avance III 300 MHz, a 
Bruker Avance III 400 MHz spectrometer, a Varian Mercury 300 MHz or a Varian Inova 500 MHz spectrometer. 
Chemical shifts are reported in ppm (δ units) referenced to the following solvent signals: DMSO-d6 δH 2.50, D2O 
δH 4.79 and CDCl3, δH 7.26. Electrospray ionization mass spectrometry (ESI-MS) for the characterization of new 
compounds was performed on a Finnigan MAT SSQ 7000 instrument or an ESI API 150EX and are reported as 
mass-per-charge ratio m/z (intensity in %, [assignment]). Accurate mass determinations (HR-MS) using ESI-MS 
were performed on a Sciex QSTAR Pulsar mass spectrometer. Infrared (IR) spectra were recorded on a Perkin 
Elmer Spectrum Two FT-IR spectrometer. Ultraviolet-visible (UV-vis) spectra were recorded on a Campsec 
M550 Double Beam Scanning UV-vis Spectrophotometer. Fluorescence measurements were performed with a 
FluoroMax-2 spectrofluorometer (Jobin-Yvon Spex) equipped with a stirrer and a temperature controller. Size 
Exclusion Chromatography (SEC) spectra were recorded on a Shimadzu Prominence LC-20A fitted with a 
Thermo Fisher Refractomax 521 Detector (Boc-P1) or a SPD20A UV-vis Detector (P1). Boc-P1 was analyzed 
using 0.05 M LiBr in DMF at 60 °C as the eluent and a flow rate of 1 mL·min-1. The instrument was fitted with a 
Polymer Labs PolarGel guard column (50 × 7.5 mm, 5 µm) followed by two PLGel PL1110-6540 columns (300 × 
7.5 mm, 5 µm). Molecular weights were calculated based on a standard calibration method using 
polymethylmethacrylate. Activation of P1 was analyzed using 100 mM acetic acid at pH 2.9 as the eluent and a 
flow rate of 1 mL·min-1. The instrument was fitted with a Shodex Asaphipak GF-510 HQ column and a Shodex 
Asaphipak GF-310 HQ column (300 × 7.5 mm, 5 µm). Vesicles were homogenized using a Mini-Extruder from 
Avanti Polar Lipids Inc. Activated polymer and Polyplex hydrodynamic diameter and ζ-potential were 
determined using a Malvern Zetasizer Nano ZS90. For cell experiments, the absorbance at 560 nm (cytotoxicity 
assays) and fluorescence (λex 489nm; λem 509nm, transfection experiments) were measured using a microplate 
reader (Infinite F2000pro Tecan). Gels were resolved on an electrophoresis cell (Fisher Scientific UK), while an 
UV image station (Chem-genius, Syngene) was used to record and analyze gel images. 
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Synthesis of Guanidinium Aldehyde (1)  
  
Scheme S1: Synthesis of aldehyde 1. a) N,N′-di-Boc-1H-pyrazole-1-carboxamidine, DIPEA, CH3CN/H2O, 55 ºC, 73%.  b) 2-
(1,3-dioxolan-2-yl)ethanamine, DCM, HBTU, DIPEA, rt, 80%. c) HCl 3M, 60 ºC, 70%.  
Compound 7. β-alanine (6) (750 mg, 8.42 mmoles) was dissolved in CH3CN/H2O (6:1, 35 mL) and treated 
with N,N′-di-Boc-1H-pyrazole-1-carboxamidine (627.3 mg, 2.03 mmoles) and N,N-diisopropylethylamine 
(DIPEA) (868 µl, 5.07 mmoles). The resulting solution was stirred for 2 h at 55 ºC. The product was extracted 
with DCM (3x 10 mL) and the solution was washed with aqueous HCl (5%, 3 x 20 mL). The organic layers were 
combined, dried over Na2SO4 and concentrated under vacuum. The residue was purified by flash chromatography 
(gradient DCM/MeOH 98:2→90:10, Rf (90:10) = 0.70) to give 675 mg of compound 7 (73%). Spectroscopic data 
matched those reported in the literature.S2 
Compound 8. A solution of 7 (520 mg, 1.57 mmoles) in DCM (30 mL) was treated with TBTU (519.67 
mg, 1.57 mmoles), 2-(1,3-dioxolan-2-yl)ethanamine (316 µl, 2.83 mmoles) and DIPEA (1 mL, 6.28 mmoles, 
added dropwise). The reaction mixture was stirred at rt under Argon atmosphere for 1 hour. The reaction crude 
was washed with aqueous HCl (5%, 3 x 20 mL) and aqueous saturated NaHCO3 (2 x 20 mL). The organic layer 
was dried with anhydrous Na2SO4, filtered and concentrated under vacuum. The residue was purified by flash 
chromatography (gradient DCM/MeOH 99:1→90:10, Rf (90:10) = 0.76) to give 542.6 mg of compound 8 (80%) 
(Figure S19). 1H-NMR (300 MHz, CDCl3) δ (ppm) 11.4 (s, 1H), 8.7 (t, 3JH,H = 4.9 Hz, 1H), 6.66-6.57 (m, 1H), 
4.8 (td, 3JH,H = 4.3, 0.7 Hz, 1H), 3.95-3.91 (2H, m), 3.85-3.81 (2H, m), 3.70-3.59 (2H, m), 3.4-3.3 (2H, m), 2.41 
(t, 3JH,H = 6.2 Hz, 2H, m), 1.86-1.84 (2H, m), 1.49 (9H, s), 1.48 (9H, s). 13C-NMR (500 MHz, CDCl3) δ (ppm) 
170.79 (s), 163.40 (s), 156.25 (s), 152.84 (s), 103.89 (d), 83.09 (s), 79.28 (s), 64.89 (t), 36.05 (t), 35.40 (t), 34.71 
(t), 32.80 (t), 28.30 (q), 28.05 (q). ESI-MS (H2O/CH3CN) m/z 431 (100, [M+H]+), 453 (20, [M+Na]+). IR (neat) ν 
max 3314 (m sh, N-H), 3124 (w, N-H), 2975 (m sh, C-O), 1721 (m sh, C=O), 1611 (s, N-H), 1409 (s, C-H), 1364 
(s, C-H), 105 (s, C-O) cm-1. 
Compound 1. A solution of compound 8 (0.69 mmoles, 300 mg) in water was treated with an aqueous 
solution of HCl (3M, 10 ml  mL). The reaction mixture was stirred at 60 ºC for 1 hour. Then the solvent was 









































fractions (Rt = 4.0  min, ) were lyophilized and stored at -20 °C to give 90 mg of compound 1 (70%) (Figure S20 
and S21). RP-HPLC [Nucleosil 100-7 C18 H2O (0.1% TFA)/CH3CN (0.1% TFA) 100:0 (0→10 min), 
100:0→75:35 (10→35 min), 0:100 (>35 min)]. Purity and characterization were confirmed by analytical RP-
HPLC, 1H-NMR and ESI-MS. 1H-NMR (300 MHz, D2O) δ (ppm) 9.53 (s, 1H), 5.00-4.77 (m, 1H), 3.40-3.25 (m, 
2H), 3.24-3.04 (m, 2H), 2.65-2.60 (m, 2H), 2.52-2.29 (m, 2H), 1.94-1.73 (m, 1H), 1.70-1.60 (m, 2H). ESI-MS 
(H2O/CH3CN) m/z 187 (100, [M+H]+, 205 (30, [M+H2O]+). HR-MS (MS): Calcd for C7H15N4O2: 187.1185; 
found: 187.1190. IR (neat) ν max 3312 (m b, N-H), 3121 (m b, N-H), 2976 (w sh, C-O), 1722 (m, C=O), 1614 (s, 
N-H), 1363 (s, C-H) 1057 (s, C-O) cm-1. NMR analysis of 1 revealed a discrete mixture of isomers due to 
potential intramolecular cyclization and/or aldehyde oligomerization.S3 Treatment of 1 with benzylhydroxylamine 
afforded the corresponding oxime 9 as a pure single product. 
 
Scheme S2. To determine the purity of the isomer mixture present in 1, this mixture was reacted with benzyl hydroxylamine 
to afford oxime 9 as a pure single product. This result suggested that all isomers of compound 4 reacted, under the coupling 
conditions, to afford the desired oxime 5. 
Compound 9. A solution of compound 1 (100 mM) in aqueous acetic acid (AcOHaq) (100 mM, pH = 4.5) 
was mixed with 1.2 equivalents of O-benzylhydroxylamine (100 mM) in DMSO. The mixture was stirred at 60 ºC 
for 2 h. The crude was purified by RP-HPLC (The collected fractions (Rt = 18.8 min) were lyophilized and stored 
at -20 °C to give 9.0 mg of compound 9 (80%) (Figures S22, S23 and S24). RP-HPLC [Nucleosil 100-7 C18 H2O 
(0.1% TFA)/CH3CN (0.1% TFA) 100:0 (0→5 min), 100:0→35:75 (5→35 min), 0:100 (>35 min)]. The presence 
and purity of the O-akyloxime 9 was checked by analytical RP-HPLC, NMR and ESI-MS. 1H-NMR (500 MHz, 
D2O) δ (ppm) 7.5 (t, 3JH,H = 6.4 Hz, 1H, Isomer E), 7.43-7.35 (5H, m), 6.85 (t, 3JH,H = 5.7 Hz; 1H, Isomer Z), 5.10 
(s, 2H, Isomer Z), 5.05 (s, 2H, Isomer E), 3.40-3.30 (m, 4H), 2.59 (dd, 3JH,H = 12.3, 6.4 Hz, 1H), 2.40-2.30 (m, 
3H). 13C-NMR (500 MHz, D2O) δ (ppm) 173.5 (s), 152.2 (d) Isomer E, 152.0 (d) Isomer Z, 137.2 (s), 137.0 (s), 
128.6 (d), 128.3 (d), 128.2 (d), 128.1 (d), 128.0 (d), 75.39 (t) Isomer Z, 75.0 (t) Isomer E, 37.4 (t), 36.0 (t) Isomer 
Z, 35.9 (t) Isomer E, 34.7 (t) Isomer E, 34.6 (t) Isomer Z, 29.2 (t), 25.7 (t). ESI-MS (H2O/CH3CN) m/z 292 (100, 
[M+H]+). HR-MS (ESI): Calcd for C14H22N5O2: 292.1771; found: 283.1768. IR (neat) ν max 3369 (m b, N-H), 





















 DMSO, 60 ºC.
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Synthesis of Activated Polymers 
• Synthesis of Poly(acryloyl hydrazide) P1  
 
Scheme S3: a) tert-butyl carbazate, EDC, H2O/THF (2:1), 25 oC, 50%. b) CTA, ACVA, DMSO, 70 oC, 73%. c) i. TFA, 25 
oC; ii. H2O, NaHCO3, 25 oC, 92%. 
Compound 11. Acrylic acid (10) (3.81 mL, 54.95 mmol) and tert-butyl carbazate (8.89 g, 65.95 mmol) 
were dissolved in a H2O/THF mixture (2:1, 180 mL) at rt. N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (EDC) (11.75 g, 61.29 mmol) was added in portions to the solution over 15 minutes and left 
stirring for 3 h. The crude reaction was extracted with EtOAc (3 x 75 mL) and the organic layer was washed with 
0.1 M HCl (3 x 75 mL), H2O (50 mL) and brine (2 x 50 mL). The organic phase was dried with anhydrous 
Na2SO4 and the solvent was removed under reduced pressure to afford the crude product as a white solid. The 
crude product was purified by recrystallization from EtOAc (70 oC to rt) to afford a 5.05 g of a white crystalline 
powder identified as 11 (50%) (Figure S25). Rf = 0.87 (100% EtOAc). 1H-NMR (300 MHz, DMSO-d6) δ (ppm) 
9.79 (s, 1H), 8.84 (s, 1H), 6.17-6.20 (m, 2H), 5.69 (dd, 3JH,H = 7.8, 4.5 Hz, 1H), 1.40 (s, 9H). 13C-NMR (100 
MHz, DMSO-d6) δ (ppm) 164.3 (s), 155.3 (s), 129.4 (d), 126.2 (t), 79.2 (s), 28.1 (q). IR (neat) ν max 3311 (m sh, 
N-H), 3221 (m sh, N-H), 2981 (w sh, C-H), 1715 (s sh, C=O), 1668 (s sh, C=O) cm-1. 
Boc-P1. A solution of 4,4’-azobis(4-cyanovaleric acid)  (ACVA) (18.4 mg, 0.064 mmol) in DMSO (1.5 
mL) and a solution of CTA (72.3 mg, 0.322 mmol) in DMSO (1.5 mL) were added sequentially to a solution of 
tert-butyl-2-acryloylhydrazine-1-carboxylate (11) (3.00 g, 16.095 mmol) in DMSO (14.88 mL). A 50 µL aliquot 
of this solution was taken at this stage to aid in the calculation of conversion. The reaction mixture was then 
sealed and degassed with Argon for 30 min. The degassed solution was left to react at 70 oC for 7 h. The reaction 
was stopped by allowing it to cool down to room temperature and by exposing it to air. A 50 µL aliquot of this 
solution was taken at this stage to aid in the calculation of conversion. The polymer was purified by dialysis 
against water. The water was removed by lyophilisation and by drying in a desiccator with P2O5 to afford 2.2 g of 
Boc-P1 (Figure S26) as an off-white powder (73% yield). UV (DMSO) λmax 300 nm. 1H-NMR (300 MHz, 
DMSO-d6) δ (ppm) 9.22 (1H, br), 8.60 (1H, br), 2.03 (1H, br), 1.41 (11H, br). Conversion 80%. Mn (DMF GPC) 
10270, ĐM (DMF GPC) 1.39. DP (UV-Vis) 45. 
− Calculation of Conversion 
50 µL aliquots of the reaction mixture were taken before and after the polymerization. These aliquots were 
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Monomer conversion was calculated by 1H-NMR spectra by comparing the integration of the vinyl proton signals 
from the monomers (5.69 and 6.19 ppm) to the integration from the aromatic groups in syringic acid (7.20 ppm). 
− Calculation of Degree of Polymerization (DP) Using UV 
DP in Boc-P1 was calculated by measuring the absorbance at 300 nm (λmax for Boc-P1), 305 nm and 310 
nm (λmax for CTA) and comparing against calibration curves using CTA (Figure S1 and Table S1). This way, the 
amount (mg·mL-1) of trithiocarbamate in Boc-P1 was estimated,† and the ratio between monomer units and end-
groups calculated. 
 
Figure S1: A) UV-vis of Boc-P1 (1.3 mg·mL-1) and CTA (0.03 mg·mL-1) solutions in DMSO. B) Calibration curves 
showing the linear relationship between absorbance and [CTA]. 
Poly(acryloyl hydrazide) P1. Trifluoroacetic acid (TFA) (15 mL) was added dropwise to poly(tert-butyl-
2-acryloylhydrazine-1-carboxylate) (Boc-P1) (1.5 g) and the yellow solution was stirred at rt for 2 h. Excess of 
TFA was removed by blowing a steady stream of Argon and the resulting oil was diluted in water (15 mL). The 
P1·TFA salt formed was neutralised by adding NaHCO3 until no foaming was observed. The colourless solution 
was allowed to stir overnight. The crude polymer was purified by dialysis against water. The water was removed 
by lyophilisation and by drying in a desiccator with P2O5 to afford 650 mg of P1 (Figure S27) as a white powder 
(92%). 1H-NMR (300 MHz, D2O) δ (ppm) 1.59-2.08 (br m, (3·DP)H), 1.01 (s, 3H), 0.95 (s, 3H). 13C-NMR (100 
MHz, D2O) δ (ppm) 174.9 (s), 40.2-40.5 (d), 34.4-35.7 (d). DP (1H-NMR) 40. IR (neat) νmax 3254 (w br, N-H), 
1609 (m br, C=O), 1428 (s sh) cm-1. 
− Calculation of DP using 1H-NMR 
DP in P1 was calculated from the 1H-NMR spectra by comparing the integration of the methyl substituents 
in the end-group (0.95 and 1.01 ppm, 6 H) to the integration from the aliphatic region in the polymer backbone 
(1.59-2.08 ppm) (Figure S2 and Table S1). 
                                                
† DP of polymerization calculated this way is approximate. Absorption (i.e. molar extinction coefficient, λmax) properties for 
CTA and P1 are not necessarily the same. Similarly, not all polymer chains will incorporate a trithiocarbamate as an end-group. 
However, the calculated value is within error of those calculated by 1H-NMR (Table S1). 




































Figure S2: 1H-NMR spectra of P1 showing the relevant region where the methyl substituents (a) and the aliphatic hydrogens 
(b) can be identified. 
Table S1 
 [M] / [CTA]a DP (conversion)b DP (UV-vis)c DP (1H-NMR)d 
Boc-P1 50:1 40 45 - 
P1 - - - 40 
a Calculated from the initial monomer and CTA concentrations used for the polymerization. 
b Calculated from the initial monomer and CTA ratio and the conversion of monomer from 1H-NMR. 
c Calculated by UV-vis against a CTA standard as the ratio of monomer to trithiocarbamate in Boc-P1 (Figure S1).  
d Calculated by 1H-NMR, using the methyl groups as an internal standard, as the ratio between monomer and end-group 
(Figure S2). 
• Conjugation of Poly(acryloyl hydrazide) with Aldehydes  
Poly(acryloyl hydrazide) (P1) in aqueous acetic acid (AcOHaq, 100 mM, pH 3.0) was reacted with 6 
equivalents of a solution of different molar fractions of 1 and hydrophobic aldehyde in DMSO. For instance, in a 
model experiment with pure guanidinium aldehyde (χ1 = 1), P1 (25 µl, 35 mM in AcOHaq) was reacted with 1 (25 
µl, 200 mM in DMSO) to afford a final concentration of activated polymer of 50 mM. In a typical experiment with a 
mixture of aldehydes (χ1 = 0.85, χ2 = 0.15), 25 µl of a solution of P1 (35 mM in AcOHaq pH 3.0) was mixed with a 
solution of 25 µl composed by 3.8 µl of a solution of hydrophobic aldehyde (200 mM in DMSO) and 21.2 µl of a 
solution of 1 (200 mM in DMSO) to give a final concentration of polymer of 50 mM (Table S2). This mixture was 
shaken at 60 ºC for 2 h. Activated polymers were used without further purification in the transport vesicle 
experiments. 
− Calculation of loading using 1H-NMR 
Loading in P1-4-imidazolecarboxaldehyde was calculated from the 1H-NMR spectra by comparing the 
integration of the residual aldehyde (9.7 ppm, XH) against the overall number of protons in that region (3H, 1H 
from aldehyde or hydrazone, 2H from 4-imidazolecarboxaldehyde ring). Signal at 6.0 ppm corresponds to the 
cyclic acetal and has been included in the overall integration. 
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Figure S3: A) 1H NMR spectra of P1 (1.3 mg/mL) incubated (< 1h) with increasing amounts of 4-imidazolecarboxaldehyde. 
From bottom: 0.3, 0.6 and 0.9 eq. of 4-imidazolecarboxaldehyde. B) Integration of residual aldehyde (9.7 ppm) against the 
overall number of protons (3H) in this region. 
− Dynamic light scattering of P1(1)85(2)15 
P1(1)85(2)15 was prepared accordingly to the general procedure for the conjugation of poly(acryloyl hydrazide) 
with aldehyde aldehydes. The final concentration in the reaction vessel was 17 mM. From this stock solution 20 µl 
were diluted with 1980 µl of MilliQ water to afford a final concentration of 17 µM of activated polymer. For DNA 
conjugates, 20 µl of 17 mM activated polymer stock solution was diluted with 1960 µl of MilliQ water and 20 µl of 2 
µM DNA from Herring sperm were added and the mixture was gently mixed by pipetting and immediately 
































Figure S4: Representative dynamic light scattering data for P1(1)85(2)15 in the absence and presence of dsDNA (Herring 
DNA). A) Autocorrelation function (ACF) curves and B) intensity distributions measured in milliQ water. [activated 
polymer] = 17 µM. C) Diameter and D) ζ-potential for representative activated polymer P1(1)85(2)15 = 3 µM at increasing 
molar fractions of isovaleraldehyde (χ2 = 0-1). 
Evaluation of Transport Across Model Membranes: Vesicle Experiments 
• Preparation of Large Unilamellar Vesicles (LUV) 
A thin lipid film was prepared by evaporating a solution of EYPC (25 mg) in MeOH/CHCl3 (1:1, 1 mL) on 
a rotary evaporator (at rt) and then in vacuo overnight. The resulting film was hydrated with 1.0 mL buffer (5 mM 
HPTS, 16.5 mM DPX, 10 mM Tris, 72 mM NaCl, pH 7.4) for more than 30 min, subjected to freeze-thaw cycles 
(5 x) and extrusions (15 x) through a polycarbonate membrane (pore size 100 nm). Extravesicular components 
were removed by gel filtration (Sephadex G-50) with 10 mM Tris, 107 mM NaCl, pH 7.4. Final conditions: ~5 
mM EYPC; inside: 5 mM HPTS, 16.5 mM DPX, 10 mM Tris, 72 mM NaCl, pH 7.4; outside: 10 mM Tris, 107 
mM NaCl, pH 7.4. 
P1(1)85(2)15
P1(1)85(2)15 + DNA





















Time / ms size / nm
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• Evaluation of Transport of Nucleic Acids across EYPC-LUV 
EYPC-LUV stock solutions (5 µl) were diluted with buffer (10 mM Tris, 107 mM NaCl, pH 7.4), placed in 
a thermostated fluorescence cuvette (25 °C) and gently stirred (total volume ~2000 µl; final lipid concentration 
~13 µM). HPTS efflux was monitored at λ 511 nm (λex 413 nm) as a function of time after addition of activated 
polymer (20 µl in DMSO/AcOH buffer, t = 25 s), nucleic acid (NA, 20 µl of 2 µM stock solution in buffer, t = 50 
s) and aqueous triton X-100 (1.2%, 40 µl, 370 µM final concentration, t = 225 s). Total experiment time = 250 s. 
Fluorescence intensities were normalized to fractional emission intensity I(t) using Equation S1. 
Equation S1: !! ! = (!! − !!)/(!! − !!) 
where I0 = It at NA addition, I∞ = It at saturation after lysis. Effective concentration for activated polymer or 
NA - EC50 - and Hill coefficient - n - were determined by plotting the fractional activity Y ( = I(t) at saturation just 
before lysis, t = 200 s) as a function of activated polymer or NA concentration [Analyte] and fitting them to the 
Hill equation (Equation S2). 
Equation S2: ! = !! + (!!"# − !!)/ 1 + !"!"[!"#$%&']
!
 
where Y0 is Y without NA (or activated polymer), Ymax is Y with an excess of activated polymer (or NA) at 
saturation, EC50 is the concentration of NA (or activated polymer) required to reach 50% activity and n is the Hill 
coefficient (Figure S5 and Table S2). 
 
Figure S5: A) Changes to fractional emission intensity I(t) for EYPC-LUVs⊃HPTS/DPX after the addition of activated 
polymer (17 µM, χ1: 0.85 and χ5: 0.15) at t = 25 sec, Herring DNA (5 µM-0.15 nM final concentrations) at t = 50 sec and 
Triton-X (370 µM final concentration) at t = 225 sec. B) Dose response curve obtained from the plot of fractional activity vs 
activated polymer concentration and fitting to the Hill equation (Equation S2) YMAX = 51.10 ± 2.3%, EC50 = 0.33 ± 0.3 µM, n 
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Figure S6: Changes to fractional emission intensity I(t) and dose-response curve for the transport of Herring DNA (2 µM) in 
EYPC-LUVs⊃HPTS/DPX in the presence of activated polymer (17 µM, χ1: 0.75 and χHydrophobic: 0.25). A) 
χHydrophobic = Benzaldehyde and in B) χHydrophobic = isovaleraldehyde (2). The increase in fluorescence observed 
immediately after the addition of activated polymer depicts membrane disruption profiles when using molar fractions of 0.25 


















Fuorescence increase after addition of only Activated Polymer (25-50 sec) suggests detergent and 











Figure S7: A) Changes to fractional emission intensity I(t) for the transport of Herring DNA (2 µM) in EYPC-
LUVs⊃HPTS/DPX in the presence of activated polymer (17 µM) prepared from χ2 (0.9-0.1) in the absence of cationic 
aldehyde (χ1 = 0). B) Same plot for activated polymers (17 µM) prepared with higher molar fractions of 2 (χ2 = 0.5, 0.75 or 











































































































































Figure S8: Changes to fractional emission intensity I(t) (A) and dose-response curve (B) for the transport of Herring DNA (2 














































Table S2: EC50 (µM), YMAX (%) and n for the transport of Herring DNA (125 µM) in EYPC-LUVs⊃HPTS/DPX with 
increasing concentrations of activated polymer P1(1)85(n)15 prepared from 15% of hydrophobic aldehyde (2-18) and 85% of 
1. All experiments were done in triplicate. P1(1)85(n)15 stands for P1: Polymer 1; (1)85: guanidinium aldehyde at a χ1 = 0.85; 
(n)15: hydrophobic aldehyde at a χn = 0.15.  
Polymer Aldehyde Number Aldehyde EC50 (µM) Ymax (%) n 
P1(1)85(2)15 2  5.73 ± 2.36 35.94 ± 7.80 1.47 ± 0.61 
P1(1)85(3)15 3  2.95 ± 2.25 28.00 ± 8.4 1.04 ± 0.57 
P1(1)85(4)15 4 
 
0.81 ± 0.05 53.50 ± 2.70 3.91 ± 0.94 
P1(1)85(5)15 5  
4.10 ± 0.74 56.00 ± 5.00 2.92 ± 1.48 
P1(1)85(12)15 12 
 
5.10 ± 1.40 23.10 ± 2.30 2.80 ± 0.17 
P1(1)85(13)15 13 
 
3.01 ± 0.61 17.74 ± 1.68 1.64 ± 0.50 
P1(1)85(14)15 14 
 
0.98 ± 0.17 26.71 ± 1.51 2.37 ± 0.89 
P1(1)85(15)15 15  
1.21 ± 0.08 48.80 ± 1.90 4.60 ± 1.19 
P1(1)85(16)15 16  
0.46 ± 0.05 50.9 ± 2.60 3.13 ± 1.02 
P1(1)85(17)15 17 
 
4.83 ± 3.30 17.58 ± 4.10 0.96 ± 0.39 
P1(1)85(18)15 18 
 




Cells Lines and Culture 
HeLa cells stably expressing enhanced green fluorescent protein (HeLa-EGFP) were maintained in 
Dulbecco´s Modified Eagle´s Medium from Life TechnologiesTM (DMEM, high glucose, GlutaMAXTM, pyruvate) 
supplemented with 10% (v/v) of fetal bovine serum (FBS) from HycloneTM (Thermo Fisher Scientific Inc) and 
500 µg·mL-1 of Geneticin® (Life TechnologiesTM). Transfection of HeLa-EGFP was performed in the same 
medium, free of serum and antibiotics. Cells incubations were performed in a water-jacketed 37 ºC/5% CO2 
incubator. 
• In Vitro Screening for siRNA Delivery  
Activated polymer stock solutions were prepared in DMSO/AcOHaq (v/v) as described above and diluted 
with DMSO to afford a range of stock solutions concentrations of (3-0.1 mM). These stock solutions were then 
sequentially diluted with DMEM medium free of serum and antibiotics to afford the final concentration in cells 
(17-0.3 µM). The solutions of siRNA/ activated polymer polyplexes were freshly prepared prior to the 
transfection experiments. 10 µl of the siRNA solution (1 µM in DMEM) and 8 µl of activated polymer solution at 
variable concentrations in DMEM, high Glucose, GlutaMAXTM, 10% (v/v) DMSO, were added to 190 µl DMEM, 
high glucose, GlutaMAXTM, and the mixture was homogenized by pipetting. Then, cell medium was aspirated 
from 96-well plate and 50 µl of the mixture was added in each well. The final concentration of DMSO in each 
well was 0.125% (v/v). After 4 hours of transfection the medium was aspirated and replaced by 100 µl of fresh 
DMEM, high glucose, GlutaMAXTM, pyruvate, supplemented with 10% (v/v) FBS. The total fluorescence 
knockdown was quantified after 72 hours in a microwell plate reader (Infinite F2000pro Tecan). For the best 
performing activated polymers, at the most efficient and less toxic concentration, siRNA solutions were prepared 
at different concentrations (Table S3). For control and normalization experiments forward transfection with 




Table S3: Conditions employed in the optimization of the transfection experiments. All experiments were done at a final 
concentration of activated polymer P1(1)!!1(2)!2 of 4 µM. 
χ2 a [siRNA] (nM)b siRNA (pmol) 








0.3 14 1.5 
0.4 14 1.5 
a Molar fraction of χ1 = 1 - χ2. b[siRNA] refers to the final concentration of siRNA. 
• Transfection in HeLa-EGFP 
HeLa-EGFP were transfected either with Ambion® Silencer® GFP (EGFP) siRNA (siEGFP) from Life 
Technologies™ or scramble RNA (siMock, All Star Negative Control) from Qiagen. 72 h post siRNA 
transfection, cell supernatant was removed and EGFP expression was measured by fluorimetry (λex 489nm; λem 
509nm). The percentage of EGFP knockdown was calculated as the percentage of fluorescence decrease observed 
in cells transfected with siEGFP compared to transfection with siMock with the same reagents at the same 
conditions. Percentage of cell viability was calculated as the percentage of remaining fluorescence in samples 
transfected with siMock compared to non-transfected cells in DMEM, high glucose, GlutaMAX™ and pyruvate, 
supplemented with 0.125% (v/v) DMSO. 
Lipofectamine® RNAiMAX was used as a positive control of siRNA transfection in the in vitro screening 
of activated polymers in HeLa-EGFP. The quality of the transfection experiments was assessed calculating the Z-
factor using Equation S3, 
Equation S3: !– !"#$%& = 1 − !(!!!!!)!!!!!  
In where µ stands for the mean value and σ for the corresponding standard deviation of relative 
fluorescence units (RFU) of both the positive (p = cells transfected with mixture of siEGFP and activated 
polymers or Lipofectamine® RNAiMAX) and negative (n = non-transfected cells in medium supplemented with 
0.125% (v/v) DMSO) controls (µp, σp, and µn, σn). A Z-factor between 0.5 and 1.0 indicates an excellent assay, 
0.5 is equivalent to a separation of 12 standard deviations between µp and µn (Figure S9). 
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Figure S9: RFUs and Z-factor for the knock-down of EGFP in HeLa-EGFP with activated polymer (χ1: 0.85 and 
χHydrophobic: 0.15) or Lipofectamine® RNAiMAX. 
 




Figure S11: Relative fluorescent units (RFUs) for the siRNA transfection experiments. In all cases and in all concentrations, 
transfection experiments were performed with siRNA (red) and siMock (negative control experiment in blue). In all cases the 
molar fractions were χ1 = 0.85 and χHydrophobic = 0.15. a) Hexanal (3), P1(1)85(3)15, b) Naphthaldehyde (4), P1(1)85(4)15, 
c) Benzaldehyde (5), P1(1)85(5)15, d) Knock-down of EGFP in HeLa-EGFP is only observed for isovaleraldehyde (2), 
P1(1)85(2)15. A satisfactory Z factor was obtained for the different concentrations: 0.3 µM: 0.91, 1 µM: 0.89, 2 µM: 0.65, 4 
µM: 0.46; 8 µM: 0.79, 17 µM: 0.88. 
To optimize the concentration of activated polymer, HeLa-EGFP were treated with siEGFP/ activated 






Figure S12: A) Transfection efficiency in HeLa-EGFP at a constant siRNA concentration (14 nM) and increasing 
concentrations of activated polymer (χ1 = 0.85 and χHydrophobic = 0.15). B) Transfection efficiency in HeLa-EGFP at a 
constant siRNA concentration (14 nM) and constant concentration of activated polymer (4 µM) prepared from different 
molar fractions of 2 (χ1 = 1- χ2). 
To optimize the concentration of siRNA, HeLa-EGFP were treated with siEGFP/ activated polymer 
polyplexes, at a constant activated polymer concentration (12.25 µM) and with variable siEGFP concentrations 
(Figure S13). 
 
Figure S13: Transfection efficiency in HeLa-EGFP at a constant concentration of activated polymer (4 µM, χ1 = 0.85 and 
χHydrophobic = 0.15) and decreasing concentrations of siEGFP. 
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Figure S14: Transfection efficiency in HeLa-EGFP at a constant concentration of activated polymer (4 µM, χ1 = 0.85 and 




















Polymer = 0.09 ng/ml




• Cell viability: MTT AssayS4 
 Cell viability was established by a standard MTT assay (Fig. S15).S4 One day before the assay, a 
suspension of HeLa-EGFP cells was plated in 96-well tissue culture plates (Costar 96 Flat Bottom Transparent 
Polystyrol) by adding 100 µl (∼30.000 cells) per well. The next day, the medium was aspirated and cells were 
incubated in DMEM containing 10% Fetal Bovine Serum (FBS) in the presence of activated polymer (50 
µl/well). After 4 h of incubation at 37ºC, the medium was aspirated and replaced by fresh medium (DMEM) 
containing 10% FBS (100 µl). Control cells were incubated with cell culture medium (100 µl final medium). The 
viability was measured by quantifying the cellular ability to reduce the water-soluble tetrazolium dye 3-4,5-
dimethylthiazole-2,5-diphenyl tetrazolium bromide (MTT) to its insoluble formazan salt as follows. At 72 h, 
MTT (5 mg/ml in PBS, 10 µl/well) was added to the wells and the cells were further incubated for 4 h. The 
supernatant was carefully removed and the water-insoluble formazan salt was dissolved in DMSO (100 µl/well). 
The absorbance at 560 nm was measured. Data points were collected in triplicate and expressed as normalized 
values for untreated control cells (100%). 
 
Figure S15: Cell viability from MTT assay in HeLa-EGFP cells at a constant siRNA concentration (14 nM). A) Increasing 
concentrations of activated polymer (χ1 = 0.85 and χHydrophobic = 0.15). B) Constant concentration of activated 




To further investigate cell viability in the presence of the parent polymer P1, the activated polymer P1(1)85(2)15 
and the Lipofectamine® RNAiMAX we performed additional viability experiments (in HeLa cells) at the working 
concentrations of the transfection experiments. Following the same protocol described above, but without medium 
replacement after the initial 4 hours, cells were incubated in the presence of either Lipofectamine® RNAiMAX P1, 
the activated polymer P1(1)85(2)15 (Figure S16). 
 
Figure S16: Comparison of cell viability (MTT assay in HeLa cells) at the working concentrations of the transfection 
experiments for the polymer and for the Lipofectamine® RNAiMAX (A), P1 (B) and Activated polymer = P1(1)85(2)15 (C). In all 
cases [siRNA] = 14 nM. 
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Characterization of Polyplexes 
• Hydrodynamic Radius and ζ-potential 
10 µl of activated polymer’s stock solutions were diluted in MilliQ water to afford the desired final 
concentrations (67-4 µM) and were mixed with a solution of siRNA (10 nM, 995 µl in MilliQ water) before 
measuring. To measure activated polymer alone, the 995 µl of siRNA solution was replaced by the same amount 
of bi-distilled water. Bi-distilled water was filtered through a nylon syringe filter (0.45 µm) before use. All 
experiments were performed at 25 ºC and the mean values and standard deviations obtained from triplicates. 
 
Figure S17: Diameter (A) and ζ-potential (B) for representative siMock/Activated polymer polyplexes. [siMock] = 14 nM. 
Activated polymer (χ1 = 0.85 and χ2 = 0.15). 
• Gel Retardation Assay 
Pre-mixed siRNA/Activated polymer polyplexes (3 pmol) were loaded onto a 2% agarose gel. The gels 
were run at 100 V for 60 min in TAE buffer (40 mM Tris, 20 mM acetic acid, and 1 mM EDTA) (Figure S18). 
 
Figure S18: Gel retardation assay. siMock (lane 1) and siMock/Activated polymer polyplexes with molar ratios of of 2 (lane 
2), 4.3 (lane 3), 8.3 (lane 4), 16.7 (lane 5), 33.3 (lane 6) and 66.7 (lane 7) were loaded. [siRNA] = 14 nM in all cases. 
[Activated polymer] = [P1(1)85(2)15] = 28 nM (lane 2), 60 nM (lane 3), 0.12 µM (lane 4), 0.23 µM (lane 5), 0.46 µM (lane 6), 






















Figure S20: RP-HPLC [Nucleosil 100-7 C18, H2O (0.1% TFA)/CH3CN (0.1% TFA) 100:0 (0→10 min), 100:0→75:35 






































Figure S22: RP-HPLC [Nucleosil 100-7 C18, H2O (0.1% TFA)/CH3CN (0.1% TFA) 100:0→80:20 (5→35 min), 0:100 (>35 
min)] for the reaction of 1 with benzyl hydroxylamine. The chromatogram after oxime formation shows the presence of the 
final compound 9 and the excess of hydroxylamine. 
  
Figure S23: RP-HPLC [Nucleosil 100-7 C18, H2O (0.1% TFA)/CH3CN (0.1% TFA) 100:0 (0→5 min), 100:0→35:75 
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